UVM Medical Center, a Vermont university hospital and medical center, serves all of
Vermont and the northern New York region. Located in Burlington, UVM Medical Center is a regional, academic healthcare center and teaching hospital in alliance with the University of Vermont.
University of Vermont Interventional Cardiology Fellowship
The fellowship training program in Interventional Cardiology is an ACGME-approved, dedicated one-year program based at UVM Medical Center, the primary teaching hospital of the University of Vermont College of Medicine. Two training positions are available each year.
The program places a significant emphasis on a variety of research areas relevant to interventional cardiology as well as providing trainees with experience in all aspects of coronary intervention.
Outstanding and Special Features of the Program
- Interventional cardiology fellows are exposed to and have substantial opportunities to participate in basic and clinical research in ischemic heart disease including evaluation of human cardiomyocyte function, examination of intracoronary markers of coagulation and platelet activation in PCI patients, the interplay of diabetes and CAD and numerous multi-center clinical trials in acute coronary syndromes and new therapeutic devices.
- The academic nature of the training environment is further underscored by frequent guest speakers at Interventional Grand Rounds. Recent speakers have included Donald Cutlip, Simon Dixon, Timothy Henry, Laura Mauri, and David Holmes.
- The Fellowship in Interventional Cardiology program at the University of Vermont has been ACGME certified for the training of interventional cardiology fellows for more than a decade. We were the first to be certified and are the longest running ACGME interventional cardiology fellowship in the New England region.
- We are model for an academic health center in a rural region. Interventional cardiology fellows may have unique exposure to issues related to time/distance from a PCI program as well as the socioeconomic issues of the rural poor.
- We are fortunate to be part of the University of Vermont which boasts one of the premier thrombosis groups in the world. Our biochemistry and medical school faculties (Drs. Russ Tracey, Ken Mann, Mary Cushman, David Schneider and Burton Sobel) allow for a unique opportunity for our interventional cardiology fellows to participate in translational research involving PCI patients.
- We have faculty members in our catheterization laboratory from both Cardiology and Vascular Surgery. Thus, our fellows receive education from two Divisions that may provide complementary perspectives on the global care of the patient with cardiovascular disease. We also collaborate closely with the cardiothoracic surgery division and share a monthly educational conference.
- We have the only 5 faculty interventional cardiologists in the State of Vermont. Thus, fellows receive focused attention from a core group of full time faculty and do not have to receive their teaching from any non-faculty practitioners.
- We treat a full range of patients (including adults with congenital heart disease) and clinical issues in a busy interventional cardiology program (>900 PCI/year by faculty) allowing large but not overwhelming fellow volume and a full range of current interventional techniques. The program allows for significant time not in the interventional laboratory (approximately 25%) and encourages breadth of clinical expertise and medical knowledge in fellows. Fellows learn techniques in coronary and peripheral intervention, radial access, diagnostic catheterization in difficult hemodynamic situations, and interventional techniques in the treatment of adults with congenital and structural heart disease.
- Fellow participate in novel research in the treatment of ischemic heart disease including numerous trials in adjunctive pharmacotherapy and drug-eluting stents.
- We offer a collegial atmosphere which provides close faculty supervision of Interventional cardiology fellows during all aspects of patient care and IC training.
- There is a limited commitment of service by interventional cardiology fellows to unrelated CVD program elements (2< weeks/year). All fellows are funded to travel and present research to one international cardiology conference.
- Fellows may participate in the Northern New England Cardiovascular Disease Study Group (NNE). The NNE is recognized as a national leader in patient-outcome research and quality improvement related to PCI. The program also participates in the Cath-PCI section of the ACC National Cardiovascular Data Registry (NCDR).
Key Faculty, Recent Research Activity
Matthew Watkins' research interests have focused on therapeutic angiogenesis, treatment of SVG disease and regional outcomes in PCI.
Recent protocols involving interventional cardiology fellows include:
- AGENT Trial (Circ, 3/02), the first trial of intracoronary gene therapy for angiogenesis in CAD.
- Ongoing clinical trials in therapeutic angiogenesis including initiation of the phase III international trial (AGENT III) and steering committee membership.
- Radial Artery approach for catheterization and PCI.
- NNE outcomes analysis including improved outcomes in SVG treatment and current regional treatment of acute MI.
Harold Dauerman's research interests have focused on coronary inflammation following PCI, the evaluation of new devices in PCI and outcomes in acute MI and cardiogenic shock.
Current protocols involving interventional cardiology fellows include:
- Several trials examining 2nd and 3rd generation drug-eluting stents, including RESOLUTE, ELEMENT, and SPIRIT.
- EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization)
- BOSS (using bicarbonate infusion to prevent acute kidney injury (National Primary Investigator)
Prospero Gogo’s research interests have focused on treatment of acute coronary syndrome and (with Dr. Dauerman) evaluating outcomes in regional systems of care for acute coronary syndrome.
Current protocols involving fellows include:
- ATLAS (rivaroxaban in the treatment of ACS)
- HUMAN-PCI (early detection algorithms of ischemic events by pacemakers and implantable cardioverter-defibrillators)
- VHAS (Vermont Heart Attack Study)
Matthew Watkins, M.D.
Prospero Gogo Jr. , M.D.
Associate Program Director